EASL 2017: Emerging Therapies for Genotype 3 HCV
Highlights of New Data From EASL 2017
Key Studies Influencing My Practice Following EASL 2017
MAGELLAN-1, Part 2: Glecaprevir/Pibrentasvir Demonstrates Promising Activity in Patients With Genotype 1 or 4 HCV Infection Who Failed Previous DAA Therapy
MAGELLAN-2: 12-Week Glecaprevir/Pibrentasvir Highly Effective in Noncirrhotic Liver and Renal Transplantation Recipients Infected With Genotype 1-6 HCV
Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
Clinical Care Options, LLC. All Rights Reserved.